Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: A retrospective study

British Journal of Haematology

Volumn 141, Issue 6, 2008, Pages 792-798

  Ege, Hilmi ^a   Gertz, Morie A ^a   Markovic, Svetomir N ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Hayman, Suzanne R ^a   Kumar, Shaji K ^a   Porrata, Luis F ^a  

^a Mayo Clinic   (United States)

Author keywords

Immunology; Lymphocytes; Malignant haematology; Multiple myeloma; Prognostic factors

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; IMMUNE STATUS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIDEMIOLOGIC METHODS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE COUNT; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS;

EID: 44249113093     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07123.x     Document Type: Article

References (48)

1. Abbas, A.K. (1979) Antigen and T lymphocytes mediated suppression of myeloma cells: model systems for regulation of lymphocyte function. Immunological Reviews, 48, 245 264.
2. Abbas, K., Perry, L.L., Bach, B.A. Greene, M.I. (1980) Idiotype-specific T cell immunity. I. Generation of effector and suppressor T lymphocytes reactive with myeloma idiotypic determinants. Journal of Immunology, 124, 1160 1166.
3. Azuma, T., Otsuki, T., Kuzushima, K., Froelich, C.J., Fujita, S. Yasukawa, M. (2004) Myeloma cells are highly senstivie to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clinical Cancer Research, 10, 7402 7412.
4. Barlogie, B., Epstein, J., Selvanayagam, P. Alexanian, R. (1989) Plasma cell myeloma-new biological insights and advances in therapy. Blood, 73, 865 879.
5. Behl, D., Porrata, L.F., Markovic, S.N., Letendre, L., Pruthi, R.K., Hook, C.C., Tefferi, A., Elliott, M.A., Kaufmann, S.H., Mesa, R.A. Litzow, M.R. (2006) Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia, 20, 29 34.
6. Boulassel, M.R., Herr, A.L., Edwards, M.D., Galal, A., Lahance, S., Laneuville, P. Routy, J.P. (2006) Early lymphocyte recovery following autologous peripheral blood stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders. Hematology, 11, 165 170.
7. Brown, R.D., Yuen, E., Nelson, M., Gibson, J. Joshua, D. (1997) The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cell in multiple myeloma. Leukemia, 11, 1312 1317.
8. Choi, C., Witzens, M., Bucur, M., Feuerer, M., Sommerfeldt, N., Trojan, A., Ho, A., Schirrmacher, V., Goldschmidt, H. Beckhove, P. (2005) Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood, 105, 2132 2134.
9. Corrado, C., Santarelli, M.T., Pavlovsky, S. Pizzolato, M. (1989) Prognostic factors in multiple myeloma: definition of risk groups in 410 previously untreated patients: A Grupo Argentino de Tratamiento de la Leucemia Aguda study. Journal of Clinical Oncology, 7, 1839 1844.
10. Corthay, A., Skovseth, D.K., Lundin, K.U., Rosjo, E., Ombolt, H., Hofgaard, P.O., Haraldsen, G. Bogen, B. (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity, 22, 371 383 (Preclinical studies).
11. Cox, D.R. (1972) Regression models and life tables. Journal of the Royal Statistical Society, Series B, 34, 187 202.
12. Crowley, J.J. McCoy, J. (1993) Survival tress by goodness of split. Journal of the American Statistical Association, 88, 457 467.
13. De Angulo, G., Hernandez, M., Morales-Arias, J., Herzog, C.E., Anderson, P., Woeff, J. Kleinerman, E.S. (2007) Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. Journal of Pediatric Hematology/Oncology, 29, 48 52.
14. Ferrandina, G., Pierelli, L., Perillo, A., Rutella, S., Ludovisi, M., Leone, G., Mancuso, S. Scambia, G. (2003) Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications. Clinical Cancer Research, 9, 195 200.
15. Fonseca, R., Harrington, D., Oken, M.M., Dewald, G.W., Bailey, R.J., van Wier, S.A., Henderson, K.J., Blood, E.A., Rajkumar, S.V., Kay, N.E., van Ness, B. Greipp, P.R. (2002) Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 (Δ13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Research, 62, 715 702.
16. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, R.A., Dewald, G.W., van Ness, B., van Wier, S.A., Henderson, K.J., Bailey, R.J. Greipp, P.R. (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 4569 4575.
17. Goodyear, O., Piper, K., Khan, N., Starczynski, J., Mahendra, P., Pratt, G. Moss, P. (2005) CD8+ T cells specific for cancer germline gene antigens are found in many patients with mulitple myeloma, and their frequency correlates with disease burden. Blood, 106, 4217 4224.
18. Gordan, L.N., Sugrue, M.W., Lynch, J.W., Williams, K.D., Khan, S.A. Mored, J.S. (2003) Correlation of early lymphocyte recovery and progressive-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplantation, 31, 1009 1013.
19. Greipp, P.R., Lust, J.A., O'Fallon, J.A., Katzmann, J.A., Witzig, T.E. Kyle, R.A. (1993) Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood, 81, 3382 3387.
20. Greipp, P.R., San Miguel, J., Durie, B.G.M., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412 3420.
21. Habermann, T.M., Payne, B.A., Klee, G.G. Pierre, R.V. (1985) Evaluation of the Coulter Model S-Plus IV. American Journal of Clinical Pathology, 84, 297 306.
22. Houet, L Veelken, H. (2006) Active immunotherapy of mulitple myeloma. European Journal of Cancer, 42, 1653 1660.
23. Jalili, A., Ozaki, S., Hara, T., Shibata, H., Hashimoto, T., Abe, M., Nishioka, Y. Matsumoto, T. (2005) Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood, 106, 3538 3545.
24. Joao, C., Porrata, L.F., Inwards, D.J., Ansell, S.M., Micallef, I.N.M., Johnston, P.B., Gastineau, D.A. Markovic, S.N. (2006) Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplantation, 37, 865 871.
25. Kaplan, E. Meier, P. (1958) Nonparametric estimation from in-complete observations. Journal of the American Statistical Association, 53, 457 481.
26. Kay, N.E., Leong, T.I., Bone, N., Vesole, D.H., Greipp, P.R., van Ness, P., Oken, M.M. Kyle, R.A. (2001) Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood, 98, 23 28.
27. Kim, H., Sohn, H.J., Kim, S.E., Kang, H.J., Park, S., Kim, S., Kim, W.K., Lee, J.S. Suh, C. (2004) Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplantation, 34, 43 49.
28. Kim, H., Sohn, H.J., Kim, S., Lee, J.S., Kim, W.K. Suh, C. (2006) Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 37, 1037 1042.
29. Kyle, R.A., Leong, T., Li, C., Oken, M.M., Kay, N.E., van Ness, B. Greipp, P.R. (2006) Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer, 106, 1958 1966.
30. Lynch, R.G. (1987) Immunoglobulin-specific suppressor T cells. Advances in Immunology, 40, 135 151.
31. Nieto, Y., Shpall, E.J., McNiece, I.K., Nawaz, S., Beaudet, J., Rosinski, S., Pellom, J., Slat-Vasquez, V., McSweeney, P.A., Bearman, S.I., Murphy, J. Jones, R.B. (2004) Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clinical Cancer Research, 10, 5076 5086.
32. Paglieroni, T. MacKenzie, M.R. (1979) In vitro cytotoxic response to human myeloma plasma cells by peripheral blood leukocytes from patients with multiple myeloma and benign monoclonal gammopathy. Blood, 54, 226 237.
33. Perez-Simon, J.A., Garcia-Sanz, R., Taberneno, M.D., Almcida, J., Gonzalez, M., Fernandez-Calvio, J., Moro, M.J., Hernandez, J.M., San Miguel, J. Orfao, A. (1998) Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood, 91, 3366 3371.
34. Porrata, L.F., Gertz, M.A., Inwards, D.J., Litzow, M.R., Lacy, M.Q., Tefferi, A., Gastineau, D.A., Dispenzieri, A., Ansell, S.M., Micallef, I.N.M., Geyer, S.M. Markovic, S.N. (2001a) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin's lymphoma. Blood, 98, 579 585.
35. Porrata, L.F., Ingle, J.N., Litzow, M.R., Geyer, S.N. Markovic, S.N. (2001b) Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplantation, 28, 865 871.
36. Porrata, L.F., Litzow, M.R., Tefferi, A., Letendre, L., Kumar, S., Geyer, S.M. Markovic, S.N. (2002a) Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia, 16, 1311 1318.
37. Porrata, L.F., Inwards, D.J., Micallef, I.N., Ansell, S.M., Geyer, S.M. Markovic, S.N. (2002b) Early lymphocyte recovery post-autologous stem cell transplantation is associated with better survival in Hodgkin's disease. British Journal of Haematology, 117, 629 633.
38. Porrata, L.F., Gertz, M.A., Litzow, M.R., Lacy, M.Q., Dispenzieri, A., Inwards, D.J., Ansell, S.M., Micallef, I.N.M., Gastineau, D.A., Elliott, M., Hogan, W.J., Hayman, S.R., Tefferi, A. Markovic, S.N. (2005) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clinical Cancer Research, 11, 1210 1218.
39. Raitakari, M., Brown, R.D., Gibson, J. Joshua, D.E. (2003) T cells in myeloma. Hematological Oncology, 21, 33 42.
40. Reichardt, V.L., Milazzo, C., Brugger, W., Einsele, H., Kang, L. Brossart, P. (2003) Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica, 88, 1139 1149.
41. van Rhee, F., Szmania, S.M., Zhan, F., Gupta, S.K., Pomtree, M., Lin, P., Batchu, R.B., Moreno, A., Spagnoli, G., Shaughnessy, J. Tricot, G. (2005) NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood, 105, 3939 3944.
42. Seong, C., Delasalle, K., Hayes, K., Weber, D., Dimopoulos, M., Swantkowski, J., Huh, Y., Glassman, A., Champlin, R. Alexanian, R. (1998) Prognostic value of cytogenetics in multiple myeloma. British Journal of Haematology, 101, 189 194.
43. Siddiqui, M., Ristow, K., Markovic, S.N., Witzig, T.E., Habermann, T.M., Colgan, J.P., Inwards, D.J., White, W.L., Ansell, S.M., Micallef, I.N., Johnston, P.B., Call, T.G. Porrata, L.F. (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. British Journal of Haematology, 134, 596 601.
44. Stewart, A.K. Fonseca, R. (2005) Prognostic and therapeutics significance of myeloma genetics and gene expression profiling. Journal of Clinical Oncology, 23, 6339 6344.
45. Wen, Y.J., Min, R., Tricot, G., Barlogie, B. Yi, Q. (2002) Tumor lysate-specific T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood, 99, 3280 3285.
46. Weng, N.-P. (2006) Aging of the immune system: how much can the adaptive immune system adapt? Immunity, 24, 495 499.
47. Witzig, T.E., Gertz, M.A., Lust, J.A., Kyle, R.A., O'Fallon, W.M. Greipp, P.R. (1996) Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood, 88, 1780 1787.
48. Yi, Q., Desikan, R., Barlogie, B. Munshi, N. (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma. British Journal of Haematology, 117, 297 305.